Higher-throughput screening with human cytochromes P450

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 1, 1999, Pages 15-19

  Crespi, Charles L ^a  

^a Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN DERIVATIVE; CYTOCHROME P450; FURAFYLLINE; KETOCONAZOLE; OXYGENASE; PHENACETIN O DEETHYLASE; QUINIDINE; QUINOLINOL DERIVATIVE; SULFAPHENAZOLE; TRANYLCYPROMINE;

DRUG METABOLISM; ENZYME INHIBITION; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; REVIEW; SCREENING;

EID: 0032902224     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. loannides C: Part 11. Cytochrome P450 families/subfamilies. In: Cytochromes P450: metabolic and toxicological aspects. loannides C (Ed). CRC Press, New York (1996) 77-300.
2. Spatzenegger M, Jaeger W: Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev (1995)27:397-417.
3. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev (1997) 29:413-580.
4. A comprehensive review of the cytochrome P450 system and its substrates/inhibitors.
5. Gonzalez FJ. Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA: Characterization of the common genetic defect in human deficient for debrisoquine metabolism. Nature (1988) 331:442-446.
6. Wrighton SA, Stevens JC, Becker GW, VandenBranden M: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylase. Arch Biochem Biophys (1993) 306:240-245.
7. Furuya H, Femandez-Salguero P, Gregory W, Taber H. Steward A, Gonzalez FJ, Idle JR: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics (1995) 5:389-392.
8. Olah TV. McLoughlin DA, Gilbert JD: The simultaneous determination of mixtures of drug candidates by liquid chrpmatography/atmospheric pressure chemcial ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom (1997) 11:17-23.
9. Berman J, Adkinson K, Shatter J: Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J Med Chem (1997) 40:827-829.
10. McLoughlin DA, Olah TV, Gilbert JD: A direct technique for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry interfaced to a Prospeky solid-phase extraction system. J Pharm Biomed >4na/(1997) 15:1893-1901.
11. Taylor EW, Gibbons JA, Braeckman RA: Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 model. Pharm Res (1997) 14:572-577.
12. Houston JB: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol (1994)47:1469-1479.
13. A demonstration of the utility of in vitro data to predict in vivo drug clearance.
14. Cariile DJ, Stevens AJ, Ashford EIL, Wagheia D, Houston JB: In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Drug MetabDisp( 1998) 26:216-221.
15. Murray M: P450 Enzymes. Inhibition mechanism, genetic regulation and effects of liver disease. Clin Pharmacokinet (1992)23:132-146.
16. Guengerich FP: Role of cytochrome P450 enzymes in drugdrug interactions. In: Drug-drug interactions: scientific and regulatory perspectives. Li AP (Ed). Academic Press, San Diego (1997) 7-35.
17. Rodrigues AD, Kukulka MJ, Surber BW, Thomas SB, Uchic JY, Rotert GA, Michael G, Thome-Kromer B, Machinist JM: Measurement of liver microsomal cytochrome P450 (CYP2D6) using [0-methyl-C]-dextromethorphan. Analyt Biochem (1994) 219:309-320.
18. Rodrigues AD, Kukulka MJ, Roberts EM, Quellet D, Rodgers TR: (O-methyl C-14)naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Disp (1996)24:126-136.
19. Rodrigues AD, Surber BW, Yao Y, Wong SL, Roberts EM: [OEthyl CJPhenacetin O-deethylase activity in human liver microsomes. Drug Metab Disp (1997) 25:1097-1100.
20. Wynalda MA, Wienkers LC: Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. DrugMetab Disp (I997) 25:1211-1214.
21. Kennedy SW, Jones SP: Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescence plate reader. Analyt Biochem (1994) 222:217-223.
22. Donato MT, Gomez-Lechon MJ, Castell JV: A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured in 96-weII plates. Analyt Biochem (1993) 213:29-33.
23. Crespi CL, Miller VP, Penman BW: Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analyt Biochem (1997) 248:188-190.
24. White INH: A continuous assay for cytochrome P-450dependent mixed function oxidases using 3-cyano 7ethoxycoumarin. >4na/y/B/oc/7e/n(1988) 172:304-310.
25. Burke MD, Meyer RT: Differential effects of phenobartitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P450 binding of phenoxazone and a homologous series of its O-alkoxy ethers. Chem-Biol Interact (1983) 45:243-258.
26. Palamanda JR, Favreau L, Lin CC, Nomeir AA: Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies. Drug Discovery Today (1998) 3:466-470.
27. Miller VP, Crespi CL: International Symposium on Microsomes and Drug Oxidations, Montpellier, France (1998) 12:325. Symposium proceedings.
28. Mayer RT, Netter KJ, Heubel F, Hahnemann B, Buchheister A, Mayer GK, Burke MD: 7-Alkoxyquinolines: new fluorescent substrates for cytochrome P450 monooxygenases. Biochem Pharmacol (1990) 40:1645-1655.
29. Korzekwa KR, Krishnamachury N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS: Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to the cytochrome P450 active sites. Biochem (1998) 37:4137-4147.
30. Results demonstrate the complexity of formation or inhibition kinetics that may be obtained with CYP3A4.
31. Wang RW, Newton DJ, Scheri TD, Lu AYH: Human cytochrome P450 3A4-catalyzed testosterone 6(beta)hydroxylation and erythromycin N-demethylation: competition during catalysis. Drug Metab Disp (1997) 25:502-507.
32. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP: Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochem (1997) 36:370-381.